M-B-025 CIRCADIAN VARIATION OF PLASMA MELATONIN ACROSS THE MENSTRUAL CYCLE IN WOMENWITH PREMENSTRUAL DYSPHORIC DISORDER

2011 ◽  
Vol 12 ◽  
pp. S29
Author(s):  
Ari Shechter ◽  
Paul L'Espérance ◽  
N.M.K. Ng Ying Kin
Keyword(s):  
Menstrual Cycle ◽  
Circadian Variation ◽  
Premenstrual Dysphoric Disorder ◽  
Plasma Melatonin

Effects Of Exogenous Melatonin On Sleep And Circadian Rhythms In Women With Premenstrual Dysphoric Disorder

SLEEP ◽  
2021 ◽  
Author(s):  
Christophe Moderie ◽  
Philippe Boudreau ◽  
Ari Shechter ◽  
Paul Lesperance ◽  
Diane B Boivin
Keyword(s):  
Menstrual Cycle ◽  
Slow Wave Sleep ◽  
Core Body Temperature ◽  
Premenstrual Dysphoric Disorder ◽  
Ovarian Hormones ◽  
Exogenous Melatonin ◽  
Plasma Melatonin ◽  
Menstrual Symptoms ◽  
The Impact ◽  
Intervention Condition

Abstract We previously found normal polysomnographic (PSG) sleep efficiency, increased slow wave sleep (SWS) and a blunted melatonin secretion in women with premenstrual dysphoric disorder (PMDD) compared to controls. Here, we investigated the effects of exogenous melatonin in five patients previously studied. They took 2 mg of slow-release melatonin 1 hour before bedtime during their luteal phase (LP) for three menstrual cycles. At baseline, patients spent every third night throughout one menstrual cycle sleeping in the laboratory. Measures included morning urinary 6-sulfatoxymelatonin (aMt6), PSG sleep, nocturnal core body temperature (CBT), visual analogue scale for mood (VAS-Mood), Prospective Record of the Impact and Severity of Menstrual Symptoms (PRISM), and ovarian hormones. Participants also underwent two 24-hour intensive physiological monitoring (during the follicular phase and LP) in time-isolation/constant conditions to determine 24-hour plasma melatonin and CBT rhythms. The same measures were repeated during their third menstrual cycle of melatonin administration. In the intervention condition compared to baseline, we found increased urinary aMt6 (p<0.001), reduced objective SOL (p=0.01), reduced SWS (p<0.001) and increased Stage 2 sleep (p<0.001). Increased urinary aMt6 was associated with reduced SWS (r=-0.51, p<0.001). Circadian parameters derived from 24-hour plasma melatonin and CBT did not differ between conditions, except for an increased melatonin mesor in the intervention condition (p=0.01). Ovarian hormones were comparable between the conditions (p≥0.28). Symptoms improved in the intervention condition, as measured by the VAS-Mood (p=0.02) and the PRISM (p<0.001). These findings support a role for disturbed melatonergic system in PMDD that can be partially corrected by exogenous melatonin.

738 Effects of exogenous melatonin on sleep, circadian rhythms, and mood in women with premenstrual dysphoric disorder

SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A288-A288
Author(s):  
Christophe Moderie ◽  
Ari Shechter ◽  
Paul Lespérance ◽  
Diane Boivin
Keyword(s):  
Menstrual Cycle ◽  
Sleep Disturbances ◽  
Slow Wave Sleep ◽  
Premenstrual Dysphoric Disorder ◽  
Ovarian Hormones ◽  
Exogenous Melatonin ◽  
Plasma Melatonin ◽  
Menstrual Symptoms ◽  
The Impact ◽  
Intervention Condition

Abstract Introduction Most women with premenstrual dysphoric disorder (PMDD) report sleep disturbances. Our group found normal polysomnographic (PSG) sleep efficiency and increased slow wave sleep (SWS) across the menstrual cycle in women with PMDD and insomnia compared to controls. Reduced melatonin levels were found in PMDD women compared to controls, with reduced secretion during their luteal phase (LP) compared to follicular phase (FP). Here, we investigated the effects of exogenous melatonin in the patients we previously studied. Methods Five patients (age, mean: 33.6, SD: 2.7) diagnosed prospectively with PMDD and insomnia participated in the study. Following a baseline assessment, patients took 2 mg of slow-release melatonin 1h before bedtime during their LP for three consecutive menstrual cycles. At baseline (treatment-free condition), patients spent every third night of their menstrual cycle sleeping in the laboratory. Measures included morning urinary 6-sulfatoxymelatonin (aMt6), PSG sleep, nocturnal core body temperature (CBT), visual analogue scale for mood (VAS-Mood), Prospective Record of the Impact and Severity of Menstrual symptoms (PRISM), subjective sleep and ovarian hormones (estrogen and progesterone). Participants also underwent two 24-hour intensive physiological monitoring (during the FP and LP) in time-isolation/constant conditions to determine 24-hour plasma melatonin and CBT rhythms. The same measures were repeated during their third menstrual cycle of melatonin administration. Results In the intervention condition compared to baseline, we found increased urinary aMt6 (p<0.001), reduced objective SOL (p=0.01), SWS (p<0.001) and increased Stage 2 sleep (p<0.001). Increased urinary aMt6 was associated with reduced SWS (r=-0.51, p<0.001). Circadian parameters derived from 24-hour plasma melatonin and CBT did not differ between conditions, except for an increased melatonin mesor in the intervention condition (p=0.01). Ovarian hormones were comparable between the conditions (p≥0.28). Symptoms improved in the intervention condition, as measured by the VAS-Mood (p=0.02) and the PRISM (p<0.001). Conclusion We have shown normalization of SWS and reduction in self-reported mood and somatic symptoms after administrating exogenous melatonin in women with PMDD. These findings support a role for disturbed melatoninergic system in PMDD that can be partially corrected by exogenous melatonin. Support (if any) This study was supported by the Canadian Institutes of Health Research (CIHR)

Trends in Research Related to Premenstrual Syndrome and Premenstrual Dysphoric Disorder: a Bibliometric Analysis

2020 ◽  
Author(s):  
Mingzhou Gao ◽  
Hui SUN ◽  
Changlong ZHANG ◽  
Dongmei GAO ◽  
Mingqi QIAO
Keyword(s):  
Systematic Review ◽  
Menstrual Cycle ◽  
Bibliometric Analysis ◽  
Young Women ◽  
Premenstrual Syndrome ◽  
Premenstrual Dysphoric Disorder ◽  
The United States ◽  
Anxiety And Depression ◽  
Publication Number ◽  
Research Hotspots

Abstract Background The global incidence of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) is increasing, with increasing suicide reports. However, the bibliometric analysis of global research on PMS and PMDD is rare. We aimed to evaluate the global scientific output of research on PMS and PMDD and to explore their research hotspots and frontiers from 1945 to 2018 using a bibliometric analysis methodology.Methods Articles with research on PMS and PMDD between 1945 and 2018 were retrieved from the Web of Science Core Collection (WoSCC). We used the bibliometric method, CiteSpace V and VOSviewer to analyze publication years, journals, countries, institutions, authors, research hotspots, and trends. We plotted the reference co-citation network, and we used keywords to analyze the research hot spots and trends.Results We identified 2,833 publications on PMS and PMDD research from 1945 to 2018, and the annual publication number increased with time, with fluctuations. Psychoneuroendocrinology published the highest number of articles. The United States ranked the highest among the countries with the most publications, and the leading institute was UNIV PENN. Keyword and reference analysis indicated that the menstrual cycle, depression and ovarian hormones were the research hotspots, whereas prevalence, systematic review, anxiety and depression and young women were the research frontiers.Conclusions We depicted overall research on PMS and PMDD by a bibliometric analysis methodology. Prevalence and impact in young women , systematic review evaluations of risk factors, and the association of anxiety and depression with menstrual cycle phases are the latest research frontiers that will pioneer the direction of research in the next few years.

scholarly journals Cognition, The Menstrual Cycle, and Premenstrual Disorders: A Review

2020 ◽  
Vol 10 (4) ◽  
pp. 198 ◽  
Author(s):  
Jessica Le ◽  
Natalie Thomas ◽  
Caroline Gurvich
Keyword(s):  
Menstrual Cycle ◽  
Cognitive Functioning ◽  
Psychological Symptoms ◽  
Premenstrual Dysphoric Disorder ◽  
Future Research ◽  
Negative Experience ◽  
Cognitive Disturbances ◽  
Brain Behavior ◽  
Convenient Model

Sex hormones, such as estrogens, progesterone, and testosterone, have a significant influence on brain, behavior, and cognitive functioning. The menstrual cycle has been a convenient model to examine how subtle fluctuations of these hormones can relate to emotional and cognitive functioning. The aim of the current paper is to provide a narrative review of studies investigating cognitive functioning in association with the menstrual cycle in biological females, with a focus on studies that have investigated cognitive functioning across the menstrual cycle in females with premenstrual mood disorders, such as premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). In line with previous reviews, the current review concluded that there is a lack of consistent findings regarding cognitive functioning across the menstrual cycle. Most studies focused on changes in levels of blood estrogen, and neglected to explore the role of other hormones, such as progesterone, on cognitive functioning. Cognitive research involving premenstrual disorders is in its infancy, and it remains unclear whether any cognitive disturbances that are identified may be attributed to negative experience of mood and psychological symptoms or be a more direct effect of hormonal dysregulation or sensitivity. Suggestions for future research are provided.

Sign in / Sign up

Export Citation Format

Share Document